A new study suggests that the HIV drug tenofovir may prevent AIDS transmission when applied rectally as a gel.
Martin Cranage of St. George''s University of London and colleagues conducted a study of macaques that were challenged with a potent monkey AIDS virus (SIV) administered rectally.
AIDS/HIV - Prevention And Transmission
Encyclopedia section of medindia explains in brief about the prevention for AIDS/HIV
Advertisement
The researchers found that most of the macaques pre-treated with rectal tenofovir gel up to 2 hours before the viral challenge were partly or totally protected from SIV infection.
Animals that were untreated or treated with a placebo gel became infected with SIV.
Some of the protected macaques were also found to developed T-cell immune responses to the virus.
![AIDS / HIV - Treatment]( "AIDS / HIV - Treatment")
Encyclopedia section of medindia explains in brief about the treatment for AIDS/HIV
The researchers say that their findings suggest that topical treatment with antiretroviral drugs before exposure might be used to prevent rectal HIV transmission in people.
They, however, concede that efficacy cannot be shown conclusively in animal studies.
They also revealed that human trials of a potential vaginal microbicide that worked well in macaques were halted recently because women using the microbicide showed increased rates of HIV infection.
Given that HIV targets activated T cells, the researchers are of the opinion that experiments should be conducted to check that the observed immune responses do not increase the likelihood of infection on later exposure before this approach can be tested in humans.
The study has been published in the journal PLoS Medicine.
Source: ANI
SRM
Some of the protected macaques were also found to developed T-cell immune responses to the virus.
AIDS / HIV - Treatment
Encyclopedia section of medindia explains in brief about the treatment for AIDS/HIV
Advertisement
The researchers say that their findings suggest that topical treatment with antiretroviral drugs before exposure might be used to prevent rectal HIV transmission in people.
They, however, concede that efficacy cannot be shown conclusively in animal studies.
They also revealed that human trials of a potential vaginal microbicide that worked well in macaques were halted recently because women using the microbicide showed increased rates of HIV infection.
Given that HIV targets activated T cells, the researchers are of the opinion that experiments should be conducted to check that the observed immune responses do not increase the likelihood of infection on later exposure before this approach can be tested in humans.
The study has been published in the journal PLoS Medicine.
Source: ANI
SRM
AIDS/HIV - Clinical Features
Encyclopedia section of medindia gives general info about HIV Clinical Features
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Drug News
Addressing the unmet needs of Parkinson's Disease by providing disease-modifying therapies could bring about a major shift in the way that patients are treated.
Microrobots could swirl through a person's blood stream, search for targeted areas to treat for various ailments.
Supplementation with multivitamins is an inexpensive way for older adults to slow down memory loss.
Some people with an aggressive blood cancer called acute myeloid leukemia (AML) may soon have a new drug option called Ivosidenib that blocks the activity of IDH1 gene.
In case of cardiac failure where the ejection fraction is greater than 40%, sacubitril/valsartan can prove to be quite beneficial